KALA BIO, Inc. (0JQ2.L) LSE

1.11

+0.14909(+15.53%)

Updated at December 04 07:14PM

Currency In USD

KALA BIO, Inc.

Address

1167 Massachusetts Avenue

Arlington, MA 02476

United States of America

Phone

781 996 5252

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

38

First IPO Date

January 29, 2018

Key Executives

NameTitlePayYear Born
Dr. R. Kim Brazzell Ph.D.Head of R&D and Chief Medical Officer703,6441953
Mr. Todd BazemorePrincipal Executive Officer & Director732,5071970
Mr. Darius Kharabi J.D., M.B.A.Chief Business Officer01980
Ms. Jill S. SteierExecutive Director of Investor Relations & Corporate Communications0N/A
Mr. Vincent KosewskiSenior Vice President of Manufacturing & Supply Chain Management01963
Mr. Josiah CraverSenior Vice President & Corporate Controller0N/A
Mr. Carl RennieExecutive Director of Account Management0N/A
Dr. Francis S. Mah M.D.Chief Medical Advisor0N/A
Dr. Justin Hanes Ph.D.Founder & Chair of the Scientific Advisory Board0N/A
Ms. Mary Reumuth CPAChief Financial Officer, Treasurer & Secretary01975

Description

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.